Find in Library

The symposium addressed the efficacy and safety of compounds currently available for treatment of hepatitis C virus (HCV) and chronic kidney disease (CKD) in North American and European countries, comparing data from trials and clinical practice. Prof Wedemeyer opened the meeting with a discussion of real-world experiences, with a focus on HCV genotypes (GTs) and resistance-associated variants (RAV). Prof Brown concentrated on trial and real-world data from patients with advanced liver disease, while Prof Craxí’s presentation focussed on chronic kidney conditions and infection. Prof Jacobson led the question and answer session and summarised the discussions.